Merit Medical Systems, Inc. MMSI
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About MMSI
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Merit Medical Systems, Inc. is a U.S.-based medical device company that develops, manufactures, and markets proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures. The company primarily operates in the medical technology and healthcare equipment industries, with a focus on minimally invasive procedures across cardiology, radiology, oncology, critical care, peripheral intervention, and endoscopy. Merit Medical generates revenue through the sale of procedure-specific devices to hospitals, physician practices, ambulatory surgery centers, and healthcare systems globally.
The company’s primary business lines include devices for interventional cardiology and radiology, embolotherapy, electrophysiology, spine and pain management, and endoscopy. Key products include inflation devices, catheters, guide wires, drainage systems, hemostasis products, embolic agents, and procedure kits. Merit Medical has positioned itself as a diversified interventional device manufacturer with a broad catalog of niche procedural products that are often integrated into physician workflows. Founded in 1987 by Fred P. Lampropoulos, the company expanded from producing custom procedure trays into a multinational medical device supplier through internal product development and targeted acquisitions.
Business Operations
Merit Medical conducts operations through a broad portfolio of interventional healthcare product categories rather than highly segmented standalone reporting units. Revenue is generated primarily through the sale of single-use disposable devices and related systems used in minimally invasive procedures. The company operates manufacturing and distribution facilities in the United States, Europe, and Asia, supporting both domestic and international sales channels. Its business includes products marketed under brands and operating groups such as Merit Oncology, Merit Endotek, and Merit Sensor technologies.
The company controls manufacturing, research and development, sterilization coordination, and global distribution capabilities for many of its products. Merit Medical has expanded its portfolio through acquisitions including CIanna Medical, Brightwater Medical, and Cook Medical’s lead management portfolio assets. It also maintains commercial and distribution relationships with hospitals and physician networks across multiple specialties. Public filings and investor disclosures indicate that the company emphasizes physician-driven innovation and integrated procedural solutions as part of its operating strategy.
Strategic Position & Investments
Merit Medical’s strategic direction has focused on expanding higher-margin product categories, increasing international penetration, and strengthening its portfolio in oncology, electrophysiology, peripheral intervention, and endoscopy. The company has invested significantly in research and development, manufacturing automation, and procedural technologies intended to support minimally invasive care trends. Growth initiatives highlighted in public filings include expanding direct sales capabilities, improving operational efficiency, and increasing adoption of proprietary products with recurring procedural demand.
Acquisitions have played a significant role in the company’s expansion strategy. Notable transactions include the acquisitions of CIanna Medical for breast cancer localization technologies and Brightwater Medical for esophageal dilation systems. Merit Medical has also invested in product categories tied to embolotherapy, electrophysiology, and image-guided interventions. The company continues to participate in emerging healthcare sectors involving outpatient procedural migration, interventional oncology, and device-assisted minimally invasive treatment pathways. While public disclosures consistently reference these priorities, some forward-looking growth expectations vary between analyst interpretations and company guidance.
Geographic Footprint
Merit Medical is headquartered in South Jordan, Utah, and maintains a global operational footprint across North America, Europe, Asia-Pacific, the Middle East, and other international markets. The company operates manufacturing, warehousing, and distribution facilities in locations including the United States, Ireland, the Netherlands, France, and China. International revenue represents a significant portion of total sales according to company filings and investor materials.
The company markets products in more than 100 countries through a combination of direct sales organizations and independent distributors. Its strongest commercial presence is in the United States and Europe, though management has identified international expansion opportunities in emerging healthcare markets and procedure-driven specialties. Merit Medical’s global distribution infrastructure supports hospitals, specialty clinics, and physician offices performing interventional procedures worldwide.
Leadership & Governance
Merit Medical was founded by Fred P. Lampropoulos, who served for decades as the company’s chief executive and remains associated with the company’s leadership history and strategic development. The company is publicly traded on the NASDAQ under the ticker MMSI and operates under a board-governed corporate structure consistent with U.S. public company governance standards. Leadership communications and public filings emphasize operational discipline, physician collaboration, innovation in minimally invasive care, and long-term shareholder value creation.
Key executives identified in recent public filings and investor disclosures include:
- Fred P. Lampropoulos – Executive Chairman
- F. Ann Millner – Independent Director and Board Leadership Roles
- Martha Aronson – Independent Director
- Brian G. Lloyd – Chief Legal Officer and Corporate Secretary
- Raul Parra – President and Chief Executive Officer
- Mark Long – Chief Financial Officer
- Joseph Wright – Chief Commercial Officer
Executive leadership has consistently communicated a strategy centered on disciplined acquisitions, product innovation, manufacturing efficiency, and expansion into higher-growth interventional procedure markets, as reflected in company earnings materials and SEC filings including annual reports on Form 10-K.